Cerebrospinal fluid ATP metabolites in multiple sclerosis

Increased axonal energy demand and mitochondrial failure have been suggested as possible causes for axonal degeneration and disability in multiple sclerosis. Our objective was to test whether ATP depletion precedes clinical, imaging and biomarker evidence for axonal degeneration in multiple sclerosis. The method consisted of a longitudinal study which included 21 patients with multiple sclerosis. High performance liquid chromatography was used to quantify biomarkers of the ATP metabolism (oxypurines and purines) from the cerebrospinal fluid at baseline. The Expanded Disability Status Scale, MRI brain imaging measures for brain atrophy (ventricular and parenchymal fractions), and cerebrospinal fluid biomarkers for axonal damage (phosphorylated and hyperphosphorylated neurofilaments) were quantified at baseline and 3-year follow-up. Central ATP depletion (sum of ATP metabolites >19.7 µmol/litre) was followed by more severe progression of disability if compared to normal ATP metabolites (median 1.5 versus 0, p< 0.05). Baseline ATP metabolite levels correlated with change of Expanded Disability Status Scale in the pooled cohort (r= 0.66, p= 0.001) and subgroups (relapsing—remitting patients: r= 0.79, p< 0.05 and secondary progressive/primary progressive patients: r= 0.69, p< 0.01). There was no relationship between central ATP metabolites and either biomarker or MRI evidence for axonal degeneration. The data suggests that an increased energy demand in multiple sclerosis may cause a quantifiable degree of central ATP depletion. We speculate that the observed clinical disability may be related to depolarisation associated conduction block.

[1]  J. Geurts,et al.  Enhanced number and activity of mitochondria in multiple sclerosis lesions , 2009, The Journal of pathology.

[2]  D. Bourdette,et al.  Axonal degeneration in multiple sclerosis: The mitochondrial hypothesis , 2009, Current neurology and neuroscience reports.

[3]  C. Polman,et al.  Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. , 2009, Clinical biochemistry.

[4]  David H. Miller,et al.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.

[5]  P. Hanson,et al.  Edinburgh Research Explorer Mitochondrial Changes within Axons in Multiple Sclerosis Mitochondrial Changes within Axons in Multiple Sclerosis , 2022 .

[6]  Peter K Stys,et al.  Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis , 2009, The Lancet Neurology.

[7]  A. Thompson,et al.  Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis , 2009, Neurology.

[8]  M. Makley,et al.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression , 2008, Journal of the Neurological Sciences.

[9]  S. Komoly,et al.  Variations in Mitochondrial DNA Copy Numbers in MS Brains , 2008, Journal of Molecular Neuroscience.

[10]  T. Vanden Berghe,et al.  Molecular mechanisms and pathophysiology of necrotic cell death. , 2008, Current molecular medicine.

[11]  A. Petzold.  CSF biomarkers for improved prognostic accuracy in acute CNS disease , 2007, Neurological research.

[12]  S. Waxman,et al.  Sodium Channel Expression Within Chronic Multiple Sclerosis Plaques , 2007, Journal of neuropathology and experimental neurology.

[13]  Massimo Filippi,et al.  MR Spectroscopy in Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[14]  K. Safranow,et al.  Oxypurine and purine nucleoside concentrations in renal vein of allograft are potential markers of energy status of renal tissue. , 2007, Archives of medical research.

[15]  A. M. Rush,et al.  A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Duchen,et al.  Induction of mitochondrial oxidative stress in astrocytes by nitric oxide precedes disruption of energy metabolism , 2005, Journal of neurochemistry.

[17]  C. Polman,et al.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  R. Neve,et al.  Nitric oxide‐induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis‐inducing factor translocation , 2004, The European journal of neuroscience.

[19]  L. Stefanis,et al.  Mechanisms of Caspase-Independent Neuronal Death: Energy Depletion and Free Radical Generation , 2003, The Journal of Neuroscience.

[20]  Stephen G Waxman,et al.  Temporal Course of Upregulation of Nav1.8 in Purkinje Neurons Parallels the Progression of Clinical Deficit in Experimental Allergic Encephalomyelitis , 2003, Journal of neuropathology and experimental neurology.

[21]  G. Giovannoni,et al.  A specific ELISA for measuring neurofilament heavy chain phosphoforms. , 2003, Journal of immunological methods.

[22]  Kenneth J. Smith,et al.  Blockers of sodium and calcium entry protect axons from nitric oxide‐mediated degeneration , 2003, Annals of neurology.

[23]  S. Waxman.  Nitric oxide and the axonal death cascade , 2003, Annals of neurology.

[24]  F Barkhof,et al.  Optimizing the association between disability and biological markers in MS , 2001, Neurology.

[25]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[26]  S. Waxman.  Acquired channelopathies in nerve injury and MS , 2001, Neurology.

[27]  J. Clark,et al.  N-Acetyl Aspartate: A Marker for Neuronal Loss or Mitochondrial Dysfunction , 1998, Developmental Neuroscience.

[28]  G. Davey,et al.  Energy Thresholds in Brain Mitochondria , 1998, The Journal of Biological Chemistry.

[29]  Á. Almeida,et al.  Glutamate neurotoxicity is associated with nitric oxide-mediated mitochondrial dysfunction and glutathione depletion , 1998, Brain Research.

[30]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[31]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[32]  G. Davey,et al.  Threshold Effects in Synaptosomal and Nonsynaptic Mitochondria from Hippocampal CA1 and Paramedian Neocortex Brain Regions , 1997, Journal of neurochemistry.

[33]  J. D. de Jong,et al.  Ischemic nucleotide breakdown increases during cardiac development due to drop in adenosine anabolism/catabolism ratio. , 1990, Journal of molecular and cellular cardiology.

[34]  S. M. Humphrey,et al.  Myocardial adenine pool depletion and recovery of mechanical function following ischemia. , 1985, The American journal of physiology.

[35]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[36]  S G Waxman,et al.  Membranes, myelin, and the pathophysiology of multiple sclerosis. , 1982, The New England journal of medicine.

[37]  Kenneth J. Smith.  Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders , 1994, Eye.

[38]  S. M. Humphrey,et al.  The influence of inhibitors of the ATP degradative pathway on recovery of function and high energy phosphate after transient ischemia in the rat heart. , 1986, Journal of molecular and cellular cardiology.